ImmunityBio, Inc. IBRX
- PD-L1 t-haNK — Triple-Negative Breast Cancer Phase 1
- PD-L1 t-haNK — Pancreatic Cancer Phase 2
- PD-L1 t-haNK — Glioblastoma Phase 1
PD-L1 (5 companies · 7 programs)
Companies with an active program directed at PD-L1.
Adagene Inc. ADAG
- ADG104 Phase 2
BriaCell Therapeutics Corp. BCTX
- Soluble CD80 Preclinical
CRESCENT BIOPHARMA, INC. CBIO
- CR-002 Preclinical
Fortress Biotech, Inc. FBIO
- UNLOXCYT Approved